Article: First-line combination of dasatinib and Peg-IFNα2b in chronic phase CML

€3.03

SKU: product-article-17956 Category: General

Description
Reviews (0)

Description

First-line combination of dasatinib and Peg-IFNα2b in chronic phase CML

Reviews

There are no reviews yet.

Be the first to review “Article: First-line combination of dasatinib and Peg-IFNα2b in chronic phase CML”

You must be logged in to post a review.

Top

Article: First-line combination of dasatinib and Peg-IFNα2b in chronic phase CML

Description

Reviews

Related products

Article: Calendar of events

Article: Highlights in melanoma

Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer

Article: Highlights in gynaecological cancers